PMV PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate
PMV PHARMACEUTICALS, INC. (PMVP) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate of 77.29% for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-12.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate · last filed 2026-05-12
- PMV PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2026-03-31 was 77.29%, a 3.65% decline year-over-year.
- PMV PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2025-03-31 was 80.22%, a 7.54% decline year-over-year.
- PMV PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2024-03-31 was 86.76%, a 8.59% increase year-over-year.
- PMV PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2023-03-31 was 79.90%, a 3.77% increase year-over-year.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 6 month |
|---|---|---|
| 2026-03-31 | 77.29% 10-Q · filed 2026-05-12 | |
| 2025-03-31 | 80.22% 10-Q · filed 2026-05-12 | |
| 2024-03-31 | 86.76% 10-Q · filed 2025-05-09 | |
| 2023-03-31 | 79.90% 10-Q · filed 2024-05-09 | |
| 2022-06-30 | 77.00% 10-Q · filed 2023-08-09 | |
| 2022-03-31 | 77.00% 10-Q · filed 2023-05-10 | |
| 2021-03-31 | 79.90% 10-Q · filed 2022-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |